News

FDA Approves Novel Sickle Cell Disease Treatment

FDA Approves Novel Sickle Cell Disease Treatment

The FDA granted accelerated approval to Oxbryta (voxelotor), a novel inhibitor of deoxygenated sickle hemoglobin polymerization, the central abnormality in patients with sickle cell disease.The Accelerated Approval pathway enables the FDA to approve drugs for serious conditions based on results showing it is likely to provide clinical benefits to patients. Yourway has extensive experience expediting clinical trials to take advantage of fast-tracked approval pathways.

Back to Index
Media

Upcoming Event

IQPC CTS

August 24-26, 2020
Brussels, Belgium

Media

Articles

The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?